BACKGROUND: Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. METHODS: A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. RESULTS: Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Those involved in physical activity (AOR 3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with SARS-CoV-2 infection. CONCLUSION: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.
BACKGROUND: Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. METHODS: A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. RESULTS: Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Those involved in physical activity (AOR 3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with SARS-CoV-2 infection. CONCLUSION: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.
Authors: Luigi Angelo Vaira; Giovanna Deiana; Alessandro Giuseppe Fois; Pietro Pirina; Giordano Madeddu; Andrea De Vito; Sergio Babudieri; Marzia Petrocelli; Antonello Serra; Francesco Bussu; Enrica Ligas; Giovanni Salzano; Giacomo De Riu Journal: Head Neck Date: 2020-04-29 Impact factor: 3.147
Authors: David R Boulware; Matthew F Pullen; Ananta S Bangdiwala; Katelyn A Pastick; Sarah M Lofgren; Elizabeth C Okafor; Caleb P Skipper; Alanna A Nascene; Melanie R Nicol; Mahsa Abassi; Nicole W Engen; Matthew P Cheng; Derek LaBar; Sylvain A Lother; Lauren J MacKenzie; Glen Drobot; Nicole Marten; Ryan Zarychanski; Lauren E Kelly; Ilan S Schwartz; Emily G McDonald; Radha Rajasingham; Todd C Lee; Kathy H Hullsiek Journal: N Engl J Med Date: 2020-06-03 Impact factor: 91.245
Authors: Virgilio Galvis; Francesca Romana Spinelli; Alejandro Tello; Claudia L Sossa; Juan D Higuera; Edgar D Gómez; Sergio E Serrano; Paul A Camacho; Federico G Velez Journal: Arch Bronconeumol (Engl Ed) Date: 2020-09-14
Authors: Henrique Pott-Junior; Mônica Maria Bastos Paoliello; Alice de Queiroz Constantino Miguel; Anderson Ferreira da Cunha; Caio Cesar de Melo Freire; Fábio Fernandes Neves; Lucimar Retto da Silva de Avó; Meliza Goi Roscani; Sigrid De Sousa Dos Santos; Silvana Gama Florêncio Chachá Journal: Toxicol Rep Date: 2021-03-09
Authors: Raha Orfali; Mostafa E Rateb; Hossam M Hassan; Mona Alonazi; Mokhtar R Gomaa; Noura Mahrous; Mohamed GabAllah; Ahmed Kandeil; Shagufta Perveen; Usama Ramadan Abdelmohsen; Ahmed M Sayed Journal: Antibiotics (Basel) Date: 2021-04-11
Authors: Andrew Bryant; Theresa A Lawrie; Therese Dowswell; Edmund J Fordham; Scott Mitchell; Sarah R Hill; Tony C Tham Journal: Am J Ther Date: 2021-06-21 Impact factor: 2.688
Authors: Sherief Abd-Elsalam; Rasha A Noor; Rehab Badawi; Mai Khalaf; Eslam S Esmail; Shaimaa Soliman; Mohamed S Abd El Ghafar; Mohamed Elbahnasawy; Ehab F Moustafa; Sahar M Hassany; Mohammed A Medhat; Haidi Karam-Allah Ramadan; Maii A S Eldeen; Mohamed Alboraie; Ahmed Cordie; Gamal Esmat Journal: J Med Virol Date: 2021-06-07 Impact factor: 20.693